However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its blockbuster growth drugs like Prolia and Xgeva.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Shares of Amgen Inc. (NASDAQ:AMGN – Get Free Report) have earned a consensus recommendation of “Hold” from the twenty-four ...

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new biosimilars or generics in 2025, as featured in the latest edition of ...

Additionally, there are plans to present various events for fans, including short-form videos, An Yujin's photo cards, a limited launch planning set, Polaroids, and merchandise products ...

Park Bo-gum mentioned, "I knew the amount of my screen time going in," adding, "Many people miss my short hairstyle from the past, and I think, ‘If only more of the young version of Gwan-sik had ...

Exelixis, Inc announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older with ...